Provider Briefing: Loreev XR Availability in 2026

If you've had patients report difficulty filling their Loreev XR prescriptions, you're hearing a pattern that many prescribers across the country have noticed. Loreev XR (extended-release Lorazepam, Almatica Pharma) is not currently listed on the FDA's official drug shortage database, yet patients consistently encounter access barriers at the pharmacy level.

This article provides a concise clinical overview of the current availability landscape, prescribing implications, cost considerations, and practical tools to help your patients access their medication — or transition to appropriate alternatives when needed.

Timeline: Loreev XR at a Glance

• August 2021: FDA approval of Loreev XR (NDA 214826) — lorazepam extended-release capsules for the treatment of anxiety disorders in adults on stable, evenly divided TID lorazepam dosing
• February 2022: 1.5 mg strength added to the approved formulations
• Current strengths: 1 mg, 1.5 mg, 2 mg, 3 mg extended-release capsules
• Patent expiry: January 8, 2034 (US Patent 8,999,393)
• Generic status: No ANDA-approved generics as of March 2026

Loreev XR was developed to address adherence challenges associated with TID dosing of immediate-release lorazepam. The extended-release formulation uses sustained-release and delayed sustained-release beads to maintain therapeutic plasma levels over a 24-hour dosing interval.

Prescribing Implications

Indication and Patient Selection

Loreev XR carries a narrow FDA indication: treatment of anxiety disorders in adults already receiving stable, evenly divided, TID lorazepam tablets. It is not approved as a first-line therapy or for benzodiazepine-naive patients. The recommended once-daily dose equals the patient's total daily immediate-release dose.

Clinical considerations when prescribing Loreev XR:

• Patients must be on stable TID lorazepam before transitioning
• The first Loreev XR dose should be administered the day after the last IR lorazepam dose
• Administered once daily in the morning, with or without food
• Capsules can be swallowed whole or opened and sprinkled on applesauce
• If clinical response is inadequate or UGT inhibitors are co-prescribed, discontinue Loreev XR and switch back to IR lorazepam tablets for dose adjustment

Key Safety Considerations

Loreev XR carries the standard three-part benzodiazepine boxed warning:

1. Opioid co-prescribing risk: Concomitant use may result in profound sedation, respiratory depression, coma, and death
2. Abuse, misuse, and addiction: Schedule IV controlled substance with abuse liability
3. Withdrawal risk: Abrupt discontinuation or rapid dose reduction can cause life-threatening withdrawal reactions

Additional prescribing precautions include monitoring for paradoxical reactions, depression emergence, and respiratory depression in patients with pulmonary disease. The 1 mg capsules contain FD&C Yellow No. 5 (tartrazine), which may cause allergic reactions in susceptible individuals. For comprehensive interaction details, refer to the Loreev XR drug interactions guide.

Current Availability Picture

The practical availability challenge with Loreev XR stems from several converging factors:

• Limited pharmacy stocking: As a newer brand-name product with modest prescription volume, many chain pharmacies do not maintain Loreev XR in their standard inventory
• No generic competition: Without generic alternatives, pharmacies can't substitute a more commonly stocked equivalent
• Controlled substance regulations: DEA Schedule IV classification adds ordering and inventory management complexity
• Prior authorization requirements: Many payers require PA or step therapy, which reduces fill rates and gives pharmacies less incentive to stock the product

It's worth noting that this is a stocking and distribution issue rather than a manufacturing shortage. Almatica Pharma has not reported supply disruptions to the FDA. The product is available through pharmaceutical wholesalers, but pharmacies must actively choose to order it.

Cost and Access Considerations

Cost is a significant barrier for many patients:

• Average cash price: $430–$565 for 30 capsules (all strengths)
• Generic IR lorazepam comparison: $5–$29 for 30 tablets
• Manufacturer copay card: Commercially insured patients may pay as low as $20/month (savings up to $215/fill)
• Uninsured savings program: $90 for 30 capsules through the manufacturer

For a patient-facing resource on cost savings, direct patients to our guide to saving money on Loreev XR.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder for Providers offers real-time pharmacy inventory search capabilities. You or your staff can help patients identify pharmacies that stock Loreev XR before sending them on a frustrating pharmacy-to-pharmacy search. This tool is particularly valuable for practices that prescribe specialty or less commonly stocked medications.

Manufacturer Resources

Almatica Pharma offers patient resources including copay assistance programs. For questions or to report adverse events, the manufacturer can be reached at 1-877-447-7979. HCP-specific information is available at loreevxrhcp.com.

Helping Patients Navigate Alternatives

When Loreev XR is unavailable or cost-prohibitive, the most straightforward clinical alternative is returning the patient to IR lorazepam tablets at the equivalent TID dose. Other options depending on clinical circumstances include:

• Clonazepam: Longer-acting benzodiazepine, BID dosing, widely available as generic ($5–$20/month)
• Buspirone: Non-benzodiazepine anxiolytic for GAD, non-controlled, but requires 2-4 weeks for full effect
• Hydroxyzine: Non-controlled anxiolytic, useful for situational anxiety, rapid onset but can be sedating

For a patient-facing resource on alternatives, see alternatives to Loreev XR.

Looking Ahead

With the Loreev XR patent expiring in January 2034, generic competition remains years away. In the interim, prescribers should be prepared for ongoing access challenges and have a plan for patients who encounter difficulty filling prescriptions. Key strategies include:

• Directing patients to Medfinder for Providers for pharmacy availability searches
• Ensuring patients are aware of the manufacturer's copay and savings programs
• Having a clear clinical protocol for transitioning patients back to IR lorazepam when Loreev XR is unavailable
• Documenting medical necessity thoroughly to support prior authorization requests

Final Thoughts

Loreev XR fills a real clinical need for patients who benefit from once-daily benzodiazepine dosing but face practical access barriers that are likely to persist through 2026 and beyond. By familiarizing yourself with the current availability landscape and equipping your practice with the right tools and alternative protocols, you can help patients maintain uninterrupted treatment.

For additional clinical resources, see our provider's guide to helping patients find Loreev XR and the provider's guide to helping patients save money on Loreev XR.